At the 2018 American Society of Hematology meeting, Daniel Pollyea from the University of Colorado School of Medicine, Denver, US, talks about data from an open-label, phase Ib, dose escalation and expansion trial, studying the safety and efficacy of venetoclax in combination with decitabine or azacitidine. Venetoclax in combination with either azacitidine or decitabine led to high rates of rapid and deep responses that were durable in patients with acute myeloid leukemia (AML) ineligible for standard induction chemotherapy.
Daniel Pollyea | ASH 2018 | Venetoclax in combination with HMAs in patients with AML ineligible for intensive therapy
Was this article informative? Thank you for your feedback!